Elon Musk Predicts Future Cost of Novo Nordisk’s Ozempic: What You Need to Know

Elon Musk Predicts Future Cost of Novo Nordisk’s Ozempic After South Park Special Portrays Drug as Luxury Item

In a bold prediction, Tesla and SpaceX CEO Elon Musk commented on the future cost of Novo Nordisk’s (NYSE:NVO) Ozempic, a popular drug used for weight loss. Musk’s comments came after a new South Park special portrayed the drug as a luxury item only accessible to the wealthy.

The comedy special titled “The End of Obesity” depicted Ozempic as a weight loss medication for affluent individuals, contrasting it with Lizzo’s music as a form of solace for those facing weight issues and economic challenges.

Musk responded to a post highlighting the special, stating, “It will become very cheap.” This statement from Musk comes as a significant prediction for the future pricing of the drug.

The South Park special debuted on May 24 in the U.S. and Canada, with availability for streaming on Paramount+, owned by Paramount Global. The portrayal of Ozempic in the special has sparked discussions about the accessibility and affordability of weight loss medications.

Over the past year, Novo Nordisk’s weight loss medications, including Wegovy and Ozempic, have contributed to the company’s stock growth. Similarly, Eli Lilly And Co’s (NYSE: LLY) weight-loss drug Mounjaro has led to an increase in its share value.

In response to the high prices of these medications, U.S. Senator Bernie Sanders previously called the drug’s cost “outrageous” and expressed concerns about its impact on healthcare systems.

Australia recently banned replica versions of popular weight-loss drugs, including Ozempic and Mounjaro, citing safety concerns.

Musk’s prediction about the future cost of Ozempic adds to the ongoing discussions about the affordability and accessibility of weight loss medications. As the debate continues, stakeholders in the healthcare industry will be closely monitoring any developments in drug pricing and availability.

Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.